An article published this week sheds new light on the neurological benefits of low doses of LSD in increasing neuroplasticity in the brain.
The new, intra-subject, placebo-controlled study looked at the effect of single low doses of LSD (5, 10, and 20 micrograms) on circulating BDNF levels in healthy volunteers.
The presence of brain-derived neurotropic factor (BDNF) in blood plasma is a queue used to measure levels of neuroplasticity in humans.
While the practice of microdosing psychedelics has received a lot of attention based on anecdotal evidence, there is a significant lack of clinical data proving its benefits beyond the placebo effect.
A recent trial involving 191 participants found that the cognitive benefits of subjects who consumed small doses of LSD were equal to those found in the cohort of patients consuming a placebo.
Research has shown possible links between BDNF levels and conditions such as depression, obsessive-compulsive disorder, Alzheimer’s disease, diabetes, Huntington’s disease, Rett syndrome, dementia, anorexia and bulimia, according to the Beckley Foundation, which co-sponsored the study with Maastricht University in the Netherlands.
Increased levels of BDNF are also associated with improved cognitive functioning and mental health as well as short and long-term memory.
“This study provides preliminary evidence that low doses of LSD increase plasma levels of BDNF in healthy volunteers for up to 6 hours after administration, suggesting a window of opportunity for a therapeutic response and cognitive improvement that may be. useful in patient populations, ”the study reads. .
Photo by Psychonaught on Wikimedia Commons